10-K Filing

CARGO THERAPEUTICS, INC. CIK: 1966494 FY 2023

Filing Information

Form Type	10-K
Accession Number	`0000950170-24-034730`
Period End Date	20231231
Filing Date	20240321
Fiscal Year	2023
Fiscal Period	FY
XBRL Instance	crgx-20231231_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 68 Income Statement 26 Cash Flow Statement 74 Stockholders Equity 29

Balance Sheet 68 line items

Line Item	Tag	Value	Unit	Period
Convertible preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$405.73M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.87M	USD	Point-in-time
Convertible preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$3.75M	USD	Point-in-time
Convertible preferred stock, shares authorized	`PreferredStockSharesAuthorized`	50.00M	shares	Point-in-time
Convertible preferred stock, shares authorized	`PreferredStockSharesAuthorized`	11.00M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$2.06M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$409.48M	USD	Point-in-time
Convertible preferred stock, shares issued	`PreferredStockSharesIssued`	810,700.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$3.93M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$2.17M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$28.22M	USD	Point-in-time
Convertible preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	810,700.00	shares	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Convertible preferred stock, aggregate liquidation preference	`PreferredStockLiquidationPreferenceValue`	$11.00M	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$3.37M	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$10.38M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	320.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	29.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	500.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	500.00M	shares	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$783.00K	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$4.39M	USD	Point-in-time
Total assets	`Assets`	$453.04M	USD	Point-in-time
Total assets	`Assets`	$10.24M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	41.21M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	1.09M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	1.09M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	41.21M	shares	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$3.48M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$5.01M	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$7.24M	USD	Point-in-time
Accrued clinical and research and development expenses	`AccruedClinicalAndResearchAndDevelopmentExpensesCurrent`	$1.65M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$3.39M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedExpensesAndOtherCurrentLiabilities`	$6.63M	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$1.01M	USD	Point-in-time
Operating lease liabilities, current	`OperatingLeaseLiabilityCurrent`	$2.28M	USD	Point-in-time
Convertible notes-related party	`ConvertibleNotesPayableToRelatedPartyCurrent`	$11.63M	USD	Point-in-time
Convertible notes	`ConvertibleNotesPayableCurrent`	$9.62M	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$12.71M	USD	Point-in-time
Financial commitment liabilities-related party	`FinancialCommitmentLiabilitiesToRelatedPartyCurrent`	$412.00K	USD	Point-in-time
Financial commitment liabilities	`FinancialCommitmentLiabilitiesCurrent`	$240.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$21.16M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$44.14M	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	$26.26M	USD	Point-in-time
Operating lease liabilities, non-current	`OperatingLeaseLiabilityNoncurrent`	$1.09M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$250.00K	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$225.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$47.65M	USD	Point-in-time
Total liabilities	`Liabilities`	$45.48M	USD	Point-in-time
Commitments and contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 13)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Convertible preferred stock, $0.001 par value; 11,000,000 shares authorized and 810,700 issued and outstanding at December 31, 2022 (aggregate liquidation preference of $11,000 at December 31, 2022)	`PreferredStockValue`	$1.00K	USD	Point-in-time
Common stock, $0.001 par value; 500,000,000 and 29,000,000 shares authorized at December 31, 2023 and 2022, respectively; 41,205,551 and 1,091,800 shares issued and outstanding at December 31, 2023 and 2022, respectively	`CommonStockValue`	$41.00K	USD	Point-in-time
Common stock, $0.001 par value; 500,000,000 and 29,000,000 shares authorized at December 31, 2023 and 2022, respectively; 41,205,551 and 1,091,800 shares issued and outstanding at December 31, 2023 and 2022, respectively	`CommonStockValue`	$1.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$11.76M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$550.49M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-145.15M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-47.00M	USD	Point-in-time
Total stockholders' equity (deficit)	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Total stockholders' equity (deficit)	`StockholdersEquity`	$-175.00K	USD	Point-in-time
Total stockholders' equity (deficit)	`StockholdersEquity`	$405.39M	USD	Point-in-time
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	`LiabilitiesAndStockholdersEquity`	$453.04M	USD	Point-in-time
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	`LiabilitiesAndStockholdersEquity`	$10.24M	USD	Point-in-time

Income Statement 26 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$29.37M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$75.79M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$5.40M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$20.92M	USD	Annual
Total operating expenses	`OperatingExpenses`	$96.71M	USD	Annual
Total operating expenses	`OperatingExpenses`	$34.77M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-34.77M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-96.71M	USD	Annual
Interest expense	`InterestExpense`	$1.60M	USD	Annual
Interest expense	`InterestExpense`	$4.94M	USD	Annual
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$8.78M	USD	Annual
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$-1.22M	USD	Annual
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$6.45M	USD	Annual
Loss on extinguishment of convertible notes	`GainsLossesOnExtinguishmentOfDebt`	$-2.32M	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-22.00K	USD	Annual
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$4.81M	USD	Annual
Net loss and comprehensive loss	`NetIncomeLoss`	$-98.15M	USD	Annual
Net loss and comprehensive loss	`NetIncomeLoss`	$-40.95M	USD	Annual
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-104.40	USD	Annual
Net loss per share attributable to common stockholders, basic	`EarningsPerShareBasic`	$-16.53	USD	Annual
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-16.53	USD	Annual
Net loss per share attributable to common stockholders, diluted	`EarningsPerShareDiluted`	$-104.40	USD	Annual
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	392,268.00	shares	Annual
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	`WeightedAverageNumberOfSharesOutstandingBasic`	5.94M	shares	Annual
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	392,268.00	shares	Annual
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	5.94M	shares	Annual

Cash Flow Statement 74 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-98.15M	USD	Annual
Net loss	`NetIncomeLoss`	$-40.95M	USD	Annual
Net change in fair value of redeemable convertible preferred stock tranche obligations	`NetChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheObligations`	$8.78M	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$3.33M	USD	Annual
Stock-based compensation expense	`ShareBasedCompensation`	$297.00K	USD	Annual
Loss on extinguishment of convertible notes	`GainsLossesOnExtinguishmentOfDebt`	$-2.32M	USD	Annual
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$2.20M	USD	Annual
Amortization of operating lease right-of-use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$1.04M	USD	Annual
Noncash interest expense	`PaidInKindInterest`	$1.60M	USD	Annual
Noncash interest expense	`PaidInKindInterest`	$4.94M	USD	Annual
Depreciation	`Depreciation`	$404.00K	USD	Annual
Depreciation	`Depreciation`	$1.49M	USD	Annual
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$1.50M	USD	Annual
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$1.01M	USD	Annual
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$-1.22M	USD	Annual
Change in fair value of derivative liabilities	`DerivativeGainLossOnDerivativeNet`	$6.45M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.59M	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.91M	USD	Annual
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$3.61M	USD	Annual
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$267.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$757.00K	USD	Annual
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$2.82M	USD	Annual
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$4.67M	USD	Annual
Accrued clinical and research and development expenses	`IncreaseDecreaseInAccruedClinicalAndResearchAndDevelopmentExpenses`	$1.22M	USD	Annual
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$3.79M	USD	Annual
Accrued expenses and other current liabilities	`IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities`	$2.17M	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-1.07M	USD	Annual
Operating lease liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-1.81M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-81.16M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-29.07M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquireProductiveAssets`	$2.72M	USD	Annual
Purchase of property and equipment	`PaymentsToAcquireProductiveAssets`	$8.28M	USD	Annual
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$715.00K	USD	Annual
Purchase of in-process research and development	`PaymentsToAcquireInProcessResearchAndDevelopment`	$558.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-8.99M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-3.28M	USD	Annual
Proceeds from issuance of common stock on initial public offering, net of commissions	`ProceedsFromIssuanceInitialPublicOffering`	$296.61M	USD	Annual
Proceeds from issuance of redeemable convertible preferred stock and tranche obligations, net of issuance costs	`ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndTrancheObligationsNetOfIssuanceCosts`	$199.92M	USD	Annual
Proceeds from issuance of convertible notes, net of issuance costs - related party	`ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCostsFromRelatedParty`	$15.95M	USD	Annual
Proceeds from issuance of convertible notes, net of issuance costs - related party	`ProceedsFromIssuanceOfConvertibleNotesNetOfIssuanceCostsFromRelatedParty`	$2.21M	USD	Annual
Proceeds from issuance of convertible notes, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$1.29M	USD	Annual
Proceeds from issuance of convertible notes, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$12.51M	USD	Annual
Proceeds from issuance of convertible preferred stock and tranche commitment, net of issuance costs	`ProceedsFromIssuanceOfConvertiblePreferredStockAndTrancheCommitmentNetOfIssuanceCosts`	$5.50M	USD	Annual
Proceeds from issuance of restricted stock awards	`ProceedsFromIssuanceOfRestrictedStockAwards`	$232.00K	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$34.00K	USD	Annual
Payment of deferred initial public offering costs	`PaymentsOfStockIssuanceCosts`	$5.47M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$34.19M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$494.58M	USD	Annual
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.83M	USD	Annual
Net increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$404.43M	USD	Annual
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$41.00K	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$41.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$405.73M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.87M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$567.00K	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$406.30M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.87M	USD	Point-in-time
Total cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$41.00K	USD	Point-in-time
Reclassification of shares of Series Seed redeemable convertible preferred stock to mezzanine equity	`ReclassificationOfSharesOfSeriesSeedRedeemableConvertiblePreferredStockToMezzanineEquity`	$9.83M	USD	Annual
Conversion of convertible notes to shares of Series A-2 redeemable convertible preferred stock	`ConversionOfConvertibleNotesToSharesOfSeriesA2RedeemableConvertiblePreferredStock`	$35.58M	USD	Annual
Reclassification of tranche obligation asset to Series A-1 redeemable convertible preferred stock	`ReclassificationOfTrancheObligationAssetToSeriesA1RedeemableConvertiblePreferredStock`	$1.91M	USD	Annual
Reclassification of tranche obligation liability to Series A-1 redeemable convertible preferred stock	`ReclassificationOfTrancheObligationLiabilityToSeriesA1RedeemableConvertiblePreferredStock`	$18.01M	USD	Annual
Conversion of redeemable convertible preferred stock into common stock on completion of initial public offering	`ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockOnCompletionOfInitialPublicOffering`	$254.11M	USD	Annual
Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$623.00K	USD	Annual
Purchase of property and equipment in accounts payable and accrued expenses and other current liabilities	`CapitalExpendituresIncurredButNotYetPaid`	$883.00K	USD	Annual
In-process research and development costs in accounts payable, accrued expenses and other current liabilities, and other non-current liabilities	`InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesAndOtherNonCurrentLiabilities`	$1.27M	USD	Annual
In-process research and development costs in accounts payable, accrued expenses and other current liabilities, and other non-current liabilities	`InProcessResearchAndDevelopmentCostsInAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesAndOtherNonCurrentLiabilities`	$383.00K	USD	Annual
Issuance of shares in exchange for in-process research and development	`StockIssued1`	$72.00K	USD	Annual
Deferred offering costs related to initial public offering included in accounts payable and accrued expenses and other current liabilities	`DeferredOfferingCostsRelatedToInitialPublicOfferingIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities`	$105.00K	USD	Annual
Deferred issuance costs for second tranche of Series A-1 redeemable convertible preferred stock in accounts payable and accrued expenses and other current liabilities	`DeferredIssuanceCostsForSecondTrancheOfSeriesA1RedeemableConvertiblePreferredStockInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities`	$74.00K	USD	Annual

Stockholders Equity 29 line items

Line Item	Tag	Value	Unit	Period
Commissions and offering costs	`CommissionsAndOfferingCosts`	$5.58M	USD	Annual
Beginning balance, shares	`TemporaryEquitySharesOutstanding`	810,700.00	shares	Point-in-time
Beginning balance, shares	`TemporaryEquitySharesOutstanding`	0.00	shares	Point-in-time
Beginning balance, amount	`TemporaryEquityCarryingAmountAttributableToParent`	$10.86M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$-175.00K	USD	Point-in-time
Beginning balance, amount	`StockholdersEquity`	$405.39M	USD	Point-in-time
Reclassification of series seed redeemable convertible preferred stock, amount	`ReclassificationOfSeriesSeedRedeemableConvertiblePreferredStockValue`	$-9.83M	USD	Annual
Issuance of common stock on initial public offering, net of commissions and offering costs	`StockIssuedDuringPeriodValueNewIssues`	$291.03M	USD	Annual
Issuance of common stock on initial public offering, net of commissions and offering costs, Shares	`StockIssuedDuringPeriodSharesNewIssues`	18.75M	shares	Point-in-time
Conversion of redeemable convertible preferred stock to common stock on initial public offering	`StockIssuedDuringPeriodValueConversionOfConvertibleSecurities`	$254.11M	USD	Annual
Conversion of redeemable convertible preferred stock to common stock on initial public offering, Shares	`StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities`	18.84M	shares	Point-in-time
Issuance of Series Seed convertible preferred stock, amount	`IssuanceOfSeriesSeedConvertiblePreferredStockValue`	$5.50M	USD	Annual
Issuance of restricted stock awards, amount	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	$3.00K	USD	Annual
Vesting of restricted stock awards	`VestingOfRestrictedStockAwardValue`	$18.00K	USD	Annual
Vesting of restricted stock awards	`VestingOfRestrictedStockAwardValue`	$103.00K	USD	Annual
Issuance of common shares for license, amount	`StockIssuedDuringPeriodValueOfCommonSharesForLicense`	$72.00K	USD	Annual
Exercise of stock options, shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	27,787.00	shares	Annual
Exercise of stock options, amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$34.00K	USD	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$297.00K	USD	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$3.33M	USD	Annual
Net loss	`NetIncomeLoss`	$-98.15M	USD	Annual
Net loss	`NetIncomeLoss`	$-40.95M	USD	Annual
Ending balance, shares	`TemporaryEquitySharesOutstanding`	810,700.00	shares	Point-in-time
Ending balance, shares	`TemporaryEquitySharesOutstanding`	0.00	shares	Point-in-time
Ending balance, amount	`TemporaryEquityCarryingAmountAttributableToParent`	$10.86M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-35.24M	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$-175.00K	USD	Point-in-time
Ending balance, amount	`StockholdersEquity`	$405.39M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.